1. Home
  2. ITIC vs MNMD Comparison

ITIC vs MNMD Comparison

Compare ITIC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Investors Title Company

ITIC

Investors Title Company

N/A

Current Price

$248.08

Market Cap

517.1M

Sector

Finance

ML Signal

N/A

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$12.61

Market Cap

960.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITIC
MNMD
Founded
1972
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
517.1M
960.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ITIC
MNMD
Price
$248.08
$12.61
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$25.78
AVG Volume (30 Days)
20.3K
1.5M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
6.32%
N/A
EPS Growth
25.81
N/A
EPS
19.00
N/A
Revenue
$273,864,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.19
N/A
Revenue Growth
13.63
N/A
52 Week Low
$190.20
$4.70
52 Week High
$288.98
$14.43

Technical Indicators

Market Signals
Indicator
ITIC
MNMD
Relative Strength Index (RSI) 41.04 55.67
Support Level $237.90 $12.19
Resistance Level $249.78 $13.45
Average True Range (ATR) 7.71 0.70
MACD -2.57 0.08
Stochastic Oscillator 26.63 72.07

Price Performance

Historical Comparison
ITIC
MNMD

About ITIC Investors Title Company

Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: